More information about AXOGEN INC.

It's time to rethink nerve repair AxoGen (AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen's portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and Avive® Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a soft tissue covering to reduce inflammation and scar tissue formation. Along with these core surgical products, AxoGen also offers AxoTouch® Two-Point Discriminator and AcroVal® Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom and several European and international countries. Company Overview - Only company focused on peripheral nerve repair solutions - Addressing a $1.6B+ current market opportunity - Comprehensive product portfolio addresses all surgical peripheral nerve reconstruction needs - Pioneering sales and market strategy, solid execution plan -Poised for strong growth - 75% gross margins - Barriers to competitive entry & growing body of clinical data - Long term expansion potential beyond current market Our Market AxoGen is a pioneer in the regenerative medicine market with a portfolio of products for peripheral nerve reconstruction. Our technologies provide an option for surgeons to reconstruct injured nerves without the comorbidities associated with an additional surgical site. Further, they offer surgeons an opportunity to protect compressed nerves or reconstruct injured nerves. Our technologies are used by several surgical specialties and in peripheral nerves throughout the body. Based on research and analysis, the U.S. market for the repair of transected peripheral nerves in the extremities exceeds $1.6 billion. AxoGen is actively targeting this market and expanding focus in OUS markets. Our Current Focus - Upper Extremity - Lower Extremity - Carpal Tunnel Revision - Oral and Maxillofacial AxoGen's future expansion opportunities include Facial Reconstruction, Podiatry, Breast Reconstruction, Prostatectomy, and Pain Management